

Sareum Holdings plc

("Sareum" or the "Company")

Exercise of Warrants

Cambridge, UK, 2 September 2026- Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to subscribe for a total of 313,509 new ordinary shares in the capital of the Company at a price of 12.5 pence per ordinary share ("**New Ordinary Shares**") for a total consideration to the Company of £39,189.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange plc for the admission of the 313,509 New Ordinary Shares to trading on AIM ("**Admission**"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Tuesday 8 September 2026. The New Ordinary Shares will rank *pari passu* with the existing ordinary shares.

Immediately following Admission, the total number of ordinary shares in issue will be 139,726,182, and the total number of voting rights will therefore be 139,726,182, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For Further Information:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Singer Capital Markets (Joint Corporate Broker)

Russell Cook/Patrick Weaver

020 7496 3000

Oberon Capital (Joint Corporate Broker)

Mike Seabrook / Nick Lovering

020 3179 5300

ICR Healthcare (Financial PR)

Jessica Hodgson / Lisa Lam / Tom Daniel

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease

The Company holds the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOELTMFTMTTMBFF